NGL Fine-Chem share price, P/E, ROE & financials

NGL Fine-Chem (NGLFINE) had a P/E of 30.6× on 6 Nov 2026, below the industry P/E of 37.3×, and the shares are 21% below their 52-week high. Sales and net profit grew 22% and 33% a year over 3 years, with ROCE of 17% and ROE of 16%. Debt is 0.37× equity, and its dividend yield is 0.1%. It is a small-cap company with a market cap of ₹1,750 Cr, ranked 12th of 15 Drug Manufacturers (General) companies by market cap; the shares rose 75% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹2,879.20
Day high: ₹2,879.20
Day low: ₹2,785.00
Prev. close: ₹2,860.20
Volume: 3.6K

Health check

5 good · 1 fair

ReturnsAhead
+75.5% over a year, better than 6 of 7 peers.
Price tagCheaper
P/E 30.6 vs industry 37.3.
GrowthStrong
Sales +21.8%, profit +32.9% a year over 3 years.
ProfitabilityAverage
ROCE 17.2% vs peer median 23.3%.
Balance sheetSolid
Debt 0.37× equity, interest covered 15.2×, Piotroski 6 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - General

14 listed peers. Screen the industry

Small cap

₹1,750 Cr, #12 of 15 in its industry by size.

Moves with the market

Beta 0.90 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Jun 2026: sales ₹536 Cr · profit ₹57 Cr

Market cap: ₹1,750 Cr; Small cap
P/E: 30.6; Industry 37.3
Price to book: 5.31; Peers 18.55
Dividend yield: 0.06%
ROE: 15.7%; Peers 20.9%
ROCE: 17.2%; Peers 23.3%
Debt to equity: 0.37; Debt ₹123 Cr
EPS (TTM): ₹92.59; Face value ₹5
OPM (TTM): 15.7%; Net margin 10.7%
Sales growth: +33.6%; Latest quarter vs a year ago
Profit growth: +99.1%; Latest quarter vs a year ago
Price to sales: 3.27; EV/EBITDA 21.4

Strengths

Quarterly profit up 99.1% on a year ago.
Quarterly sales up 33.6% on a year ago.
Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About NGL Fine-Chem

NGL Fine-Chem Limited develops and manufactures veterinary APIs, human APIs, intermediates, and finished dosage forms in India, Europe, the Asia Pacific, the United States, and internationally. The company offers afoxolaner, amitraz, atovaquone, buparvaquone, butaphosphan, carprofen, clorsulon, closantel base, closantel sodium, decoquinate, diminazene diaceturate, febantel, fenbendazole, fluazuron, flumethrin, flunixin meglumine, fluralaner, halquinol,…

Headquarters: Mumbai
Employees: 498
Sector: Healthcare
ISIN: INE887E01022
Website: nglfinechem.com

Price range

52 weeks

₹1,271.00₹3,602.00

Today

₹2,785.00₹2,879.20

Avg volume (3M): 12.2K
1-year return: plus 75.5%
From 52-week high: minus 21.4%

Peers · Drug Manufacturers - General

Compare with peers Screen the whole industry

Company
GLAXOGlaxosmithkline Pharmaceuticals	2,524.80	plus 0.98%	42,772	37.3	22.73	55.4%	63.9%	34.1%	5.7%	19.3%	2.26%	minus 6.0%
RUBICONRubicon Research	1,659.30	minus 4.67%	27,468	95.6	19.38	23.6%	19.1%	23.3%	–	–	0.09%	plus 166.7%
PFIZERPfizer	3,856.00	minus 0.02%	17,640	23.2	4.02	22.9%	20.9%	36.7%	1.3%	5.0%	1.94%	minus 24.6%
CORONACORONA Remedies	2,441.10	plus 2.58%	14,930	72.1	18.55	29.0%	28.3%	21.3%	16.6%	29.7%	0.41%	plus 69.7%
MARKSANSMarksans Pharma	303.70	minus 3.20%	13,764	24.6	4.13	17.5%	15.2%	22.5%	16.7%	16.2%	0.30%	plus 68.0%
SYMBIOTECSymbiotec Pharmalab	1,513.60	plus 19.04%	9,726	103.5	8.26	14.3%	11.2%	10.7%	16.8%	67.3%	0.00%	plus 37.9%
SANOFICONRSanofi Consumer Healthcare India	3,420.20	minus 0.69%	7,888	28.2	22.64	–	80.4%	37.8%	–	–	2.19%	minus 29.5%
NGLFINENGL Fine-Chem	2,832.40	minus 0.97%	1,750	30.6	5.31	17.2%	15.7%	15.7%	21.8%	32.9%	0.06%	plus 75.5%
Median of 7 peers	–	−0.02%	14,930	37.3	18.55	23.3%	20.9%	23.3%	16.6%	19.3%	0.41%	37.9%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
104	120	128	149	139
93.2	103	105	128	116
11	17.2	22.3	21.4	23.3
10.5%	14.3%	17.5%	14.3%	16.7%
6.4	2.1	4.6	2.5	7.4
1.2	1.2	1.1	1	1
4.3	5.1	5.2	5.1	5.3
11.8	13	20.7	17.8	24.5
21.9%	25.7%	24.1%	24.3%	24.8%
9.2	9.6	15.7	13.5	18.4
14.96	15.58	25.40	21.83	29.78

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +21.8%
Profit CAGR 3Y: +32.9%
EPS CAGR 3Y: +32.9%
ROE: 15.7%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
274	334	363	494
–	+22.0%	+8.8%	+36.1%
239	280	328	414
35	53.7	35.1	80.3
12.8%	16.1%	9.7%	16.2%
4.9	6.3	7.1	14.1
1.2	1.3	2.3	4.5
11.3	11.6	12.5	19.6
–	7.3	0.3	−6.9
27.4	54.4	27.7	63.4
25.1%	24.1%	23.8%	24.1%
20.5	41.3	21.1	48.1
–	+101.6%	minus 48.9%	+127.8%
33.18	66.88	34.19	77.90

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
3.1	3.1	3.1	3.1
219	260	279	326
32.5	34	77.7	123
32	58.9	74.6	93.7
287	356	435	545
115	134	192	258
27.8	48.5	49.8	94.6
4.4	4.6	1	9.3
47.6	55	61	41.9
92	114	131	141
287	356	435	545

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
35.3	20.5	32.4	43.3
−27	−26.8	−69.7	−70.6
−1.1	−1.1	37.5	29.5
7.2	−7.4	0.1	2.3
−31.4	−28.5	−74.3	−89.9
3.9	−8.1	−41.9	−46.5
−1.1	−1.1	−1.1	−1.1

Shareholding pattern

Source: NSE filings

72.5%

promoters

Promoters72.49%
Public27.51%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	72.49%	27.51%	0.00
30 Jun 2026	72.49%	27.51%	minus 0.25
31 Mar 2026	72.74%	27.26%	0.00
31 Dec 2025	72.74%	27.26%	0.00
30 Sep 2025	72.74%	27.26%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you